In our study, patients with late-stage breast cancer exhibited significantly higher levels of CEA, CA125 and CA15-3 compared with early-stage ones, suggesting that the serum levels of these tumor markers might be more efficient for monitoring advanced tumors than early diagnosis. The gene discussed is CEACAM5; the disease is breast carcinoma.